ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Despite that tyrosine kinase inhibitors such as imatinib targeting BCR-ABL oncoprotein have ameliorated survival effectively [6], the TKI-resistance and uncontrolled progression prevent part of CML patients from curative benefit [8, 37].